Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study

An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study

The purpose of this trial is to assess the safety profile of Cvac for epithelial ovarian cancer patients who were enrolled in the Cvac clinical trial CAN-003 and are no longer eligible for study participation due to disease progression.

Inclusion Criteria:

• Female patients ≥ 18 years old with histologically confirmed Stage III or IV epithelial ovarian, primary peritoneal, or fallopian tube cancer who were enrolled in CAN-003
• Able and willing to undergo mononuclear cell (MNC) collection (if required for patients who do not have available Cvac doses)
• Were enrolled in CAN-003 and met protocol criteria for progressive disease
• Wish to remain in the study and, in the investigator's judgment, the potential benefit of Cvac treatment outweighs the risk
• Must be non-pregnant and, if of childbearing potential, must use adequate birth control (hormonal or barrier method of birth control or abstinence) for the duration of the study and for 3 months after study completion
• Able to provide written informed consent
• White blood cell count (WBC) ≥ 3.0 K/μL, absolute neutrophil count ≥ 1.5 K/μL, hemoglobin ≥ 9.0 g/dL, and platelets ≥100,000/mm^3

Exclusion Criteria:

• Pregnant or breastfeeding
• Other medical conditions which preclude study participation, in the opinion of the investigator
• Receiving treatment with any other investigational product